Cytokinetics Announces New Results From COSMIC-HF To Be Presented At The American Heart Association Scientific Sessions 2016

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Cytokinetics, (Nasdaq:CYTK) today announced that a new analysis of left atrial structure and function from COSMIC-HF ( Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, will be presented on November 14 at the American Heart Association (AHA) Scientific Sessions in New Orleans, LA.

Abstract Title: Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Atrial Structure and Function in Chronic Heart Failure (COSMIC-HF) Abstract Number: M 4180 Session Title: Impact of Novel Therapies on Cardiac Structure and Function Location: Science and Technology Hall, Clinical Science Section Date: Monday, November 14, 2016 Time: 2:00 - 3:15 PM

About Omecamtiv Mecarbil

Omecamtiv mecarbil is a novel cardiac myosin activator. Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction. Cardiac myosin activators are thought to accelerate the rate-limiting step of the myosin enzymatic cycle and shift the enzymatic cycle in favor of the force-producing state. Preclinical research has shown that cardiac myosin activators increase contractility in the absence of changes in intracellular calcium in cardiac myocytes.

If you liked this article you might like

Biotech Movers: Anika Up on Strong Analyst Ratings

Merger Buzz Drives Akorn to Top of Health Chart in April

Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers

These Stocks Are Trending Up With Monster Volume

7 Stocks Trending Up With Monster Volume